Please assess the completion status of the following clinical trial:

Trial Title: DC Vaccine in Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically-confirmed stage I and II hypermutated colorectal cancer (CRC)~* Surgically resected disease~* Male or female patients 18+ years of age~* ECOG performance status 0-1~* Certain laboratory values, performed within 14 days prior to consent~* Subjects of reproductive potential must agree to use a medically accepted birth control method during the trial and for at least two months following the trial.~* Provide written informed consent~Exclusion Criteria:~* Prior malignancy within 3 years that may put subject at risk~* Pregnant or nursing women~* Concurrent treatment with systemic immunosuppressants including corticosteroids, calcineurin inhibitors, antiproliferative agents within 2 weeks of consent. Local (inhaled or topical) steroids or replacement dose prednisone are permitted.~* Known allergy to eggs~* Any uncontrolled intercurrent illness or active ongoing infection thta may put subject at additional risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All subjects (Type: EXPERIMENTAL): All subjects will receive the vaccine and be followed per the schedule of procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).